Agenus

AGEN

Market cap $208M

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The studies span neoadjuvant colorectal cancer, refractory metastatic colorectal cancer and advanced sarcoma, re.

Agenus pivots to prioritize BOT+BAL in neoadjuvant MSS colon cancer, targeting earlier, curative-intent treatment for a higher probability of durable outcomes. The recent $85M private placement and potential warrant exercises de-risk AGEN's balance sheet, extending the runway to 2031 and aligning capital with key Phase 3 ROBBIN trial milestones. The Phase 3 ROBBIN trial aims to validate BOT+BAL's strong early-stage efficacy in high-risk Stage II/III MSS colon cancer, with event-free survival as the primary endpoint.

Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.

Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript

Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its botensilimab and balstilimab (BOT+BAL) immunotherapy combination in microsatellite-stable (MSS) colon cancer. The financing includes approximately $85 million in upfront gross proceeds, with an additional potential $255 million available through the full exercise of purchase warrants.

Agenus Inc. (NASDAQ:AGEN) stock surged over 100% in intraday trading on Monday after the immuno-oncology company unveiled an $85 million private placement that could grow to $340 million if investors fully exercise accompanying warrants.

Agenus NASDAQ: AGEN said it is shifting its development focus and financial resources toward a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab, known as BOT/BAL, in high-risk stage 2 and stage 3 microsatellite stable colon cancer.

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and L.

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The data were presented at the European Society fo.